Read more
1:42 PM · 12 November 2025

Chart of the day: US30 (12.11.2025)

Key takeaways
US30
Indices
-
-
Merck
Stocks
MRK.US, Merck & Co Inc
-
-
Apple
Stocks
AAPL.US, Apple Inc
-
-
Key takeaways
  • The US30 is extending its gains after reaching a record closing level yesterday.
  • The index is supported by a capital rotation from the technology sector into traditional value stocks.
  • Among yesterday’s top performers on Wall Street were biotech stocks, which continue their strong momentum in premarket trading.

The US30 continues its upward momentum after closing yesterday’s session at a record high of around 48,000 (+1.3%), driven by a massive rotation of capital across Wall Street. While the potential end of the U.S. government shutdown supports broad market optimism, persistent concerns over high valuations in the AI sector have redirected capital toward more traditional value stocks.

The US30 successfully broke above the 30-day exponential moving average, consolidating its position by closing above the previously established resistance near 47,860. Holding above the psychological level of 48,000 will be key for further gains toward the upper boundary of the recent technical structure, though the RSI entering overbought territory may limit optimism for the index’s value-oriented names. (Source: xStation5)

 

What’s driving the US30 today?

  • The U.S. House of Representatives (the lower chamber of Congress) will vote today on the Senate’s federal funding bill, whose approval could pave the way to ending the more than 40-day government shutdown. The bill provides for full federal funding through January 2026, an annual budget for key agencies, and the payment of frozen wages to federal employees.

  • The Dow Jones Industrial Average, like other major U.S. indices, returned to gains early this week after the bill passed the Senate with the support of eight moderate Democrats. However, the broad market euphoria proved short-lived, as Tuesday saw a massive rotation of capital from growth stocks into more defensive sectors such as consumer staples and healthcare.

  • The technology sector remains weighed down by valuation concerns, as shown by Nvidia’s nearly 3% drop yesterday, deepened by SoftBank’s complete divestment of its Nvidia stake and disappointing results from AI cloud provider CoreWeave.

  • The new record high for the DJIA was primarily driven by biotech stocks, which led gains during yesterday’s session (Merck & Co.: +4.8%, Amgen: +4.6%, Johnson & Johnson: +2.9%). The only decliners in the index were Nvidia, JPMorgan, Caterpillar, and Cisco. Interestingly, the tech sell-off spared Apple (+1.7%), which, as a hardware and product-based company, straddles both growth and value characteristics.

18 November 2025, 3:40 PM

Chart of the day: USDJPY (18.11.2025)

18 November 2025, 12:44 PM

AI Battle: Huawei vs Nvidia

18 November 2025, 10:44 AM

Morning Wrap (18.11.2025)

17 November 2025, 10:58 PM

Daily summary: Risk assets keep sliding on US rate cut jitters (17.11.2025)

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 2 000 000 investors from around the world